These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 33738096)

  • 21. Inhaled treprostinil vs iloprost: Comparison of adherence, persistence, and health care resource utilization in patients with pulmonary arterial hypertension.
    Burger CD; Wu B; Classi P; Morland K
    J Manag Care Spec Pharm; 2023 Jan; 29(1):101-108. PubMed ID: 36580122
    [No Abstract]   [Full Text] [Related]  

  • 22. INSPIRE: Safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH).
    Hill NS; Feldman JP; Sahay S; Benza RL; Preston IR; Badesch D; Frantz RP; Patel S; Galloway A; Bull TM;
    Pulm Circ; 2022 Jul; 12(3):e12119. PubMed ID: 36034402
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of inhaled treprostinil on risk stratification with noninvasive parameters: a post hoc analysis of the TRIUMPH and BEAT studies.
    Tonelli AR; Sahay S; Gordon KW; Edwards LD; Allmon AG; Broderick M; Nelsen AC
    Pulm Circ; 2020; 10(4):2045894020977025. PubMed ID: 33403101
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inpatient Initiation of Oral Treprostinil in an Academic Medical System.
    Hohlfelder B; Tonelli AR; Heresi GA; Bair N; Rahaghi FF; Bauer SR
    Cardiovasc Drugs Ther; 2020 Aug; 34(4):547-553. PubMed ID: 32424651
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical utility of treprostinil in the treatment of pulmonary arterial hypertension: an evidence-based review.
    Buckley MS; Berry AJ; Kazem NH; Patel SA; Librodo PA
    Core Evid; 2014; 9():71-80. PubMed ID: 25018685
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Parenteral treprostinil induction for rapid attainment of therapeutic doses of oral treprostinil.
    Miller CE; Franco V; Smith JS; Balasubramanian V; Kingrey J; Zolty R; Melendres-Groves L; Huston J; Elwing JM; Ravichandran A; Cella D; Shen E; Seaman S; Thrasher CM; Broderick M; Oudiz RJ
    Respir Med; 2023 Nov; 218():107374. PubMed ID: 37532157
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension.
    Channick RN; Olschewski H; Seeger W; Staub T; Voswinckel R; Rubin LJ
    J Am Coll Cardiol; 2006 Oct; 48(7):1433-7. PubMed ID: 17010807
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension.
    Benza RL; Seeger W; McLaughlin VV; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubin LJ
    J Heart Lung Transplant; 2011 Dec; 30(12):1327-33. PubMed ID: 22055098
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The potential for inhaled treprostinil in the treatment of pulmonary arterial hypertension.
    Gessler T; Seeger W; Schmehl T
    Ther Adv Respir Dis; 2011 Jun; 5(3):195-206. PubMed ID: 21300738
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Rapid Initiation, Titration, and Transition from Intravenous to Oral Treprostinil in a Patient with Severe Pulmonary Arterial Hypertension.
    Gleason JB; Dolan J; Piran P; Rahaghi FF
    Case Rep Pulmonol; 2015; 2015():498981. PubMed ID: 26457220
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial.
    Tapson VF; Jing ZC; Xu KF; Pan L; Feldman J; Kiely DG; Kotlyar E; McSwain CS; Laliberte K; Arneson C; Rubin LJ;
    Chest; 2013 Sep; 144(3):952-958. PubMed ID: 23669822
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.
    Tapson VF; Torres F; Kermeen F; Keogh AM; Allen RP; Frantz RP; Badesch DB; Frost AE; Shapiro SM; Laliberte K; Sigman J; Arneson C; Galiè N
    Chest; 2012 Dec; 142(6):1383-1390. PubMed ID: 22628490
    [TBL] [Abstract][Full Text] [Related]  

  • 33. One-year experience with intravenous treprostinil for pulmonary arterial hypertension.
    Benza RL; Tapson VF; Gomberg-Maitland M; Poms A; Barst RJ; McLaughlin VV
    J Heart Lung Transplant; 2013 Sep; 32(9):889-96. PubMed ID: 23953817
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and Tolerability of a Rapid Transition From Intravenous Treprostinil to Oral Selexipag in Three Adolescent Patients With Pulmonary Arterial Hypertension.
    Colglazier E; Ng AJ; Parker C; Nawaytou H; Fineman JR
    J Pediatr Pharmacol Ther; 2021; 26(5):512-516. PubMed ID: 34239406
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel dose-response analyses of treprostinil in pulmonary arterial hypertension and its effects on six-minute walk distance and hospitalizations.
    Ramani G; Cassady S; Shen E; Broderick M; Wasik A; Sui Q; Nelsen A
    Pulm Circ; 2020; 10(3):2045894020923956. PubMed ID: 35154662
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan.
    Benza RL; Rayburn BK; Tallaj JA; Pamboukian SV; Bourge RC
    Chest; 2008 Jul; 134(1):139-45. PubMed ID: 18403673
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension.
    Melnick L; Barst RJ; Rowan CA; Kerstein D; Rosenzweig EB
    Am J Cardiol; 2010 May; 105(10):1485-9. PubMed ID: 20451700
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transition from treprostinil to selexipag in patients with pulmonary arterial hypertension: Case series.
    Fanous SM; Janmohamed M
    Am J Health Syst Pharm; 2018 Dec; 75(23):1877-1881. PubMed ID: 30301721
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transitioning From Intravenous to Subcutaneous Prostacyclin Therapy in Neonates With Severe Pulmonary Hypertension.
    Turbenson MN; Radosevich JJ; Manuel V; Feldman J
    J Pediatr Pharmacol Ther; 2020; 25(7):647-653. PubMed ID: 33041721
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An observational study of inhaled-treprostinil respiratory-related safety in patients with pulmonary arterial hypertension.
    Zamanian RT; Levine DJ; Bourge RC; De Souza SA; Rosenzweig EB; Alnuaimat H; Burger C; Mathai SC; Leedom N; DeAngelis K; Lim A; De Marco T
    Pulm Circ; 2016 Sep; 6(3):329-37. PubMed ID: 27683610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.